New drug shows promise for slowing lung scarring
NCT ID NCT03865927
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tested an experimental drug called GKT137831 in 58 people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing difficult. The drug aims to reduce lung damage caused by harmful molecules called reactive oxygen species. Researchers measured changes in blood markers of stress and collagen breakdown to see if the drug could slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Temple University Medical Center
Philadelphia, Pennsylvania, 19140, United States
-
Tulane University Medical Center
New Orleans, Louisiana, 70112, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Michigan Medical Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.